Dermata Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
DRMA$0.71-7.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets: | ||
| Cash and cash equivalents | $7,438,135 | $6,241,294 |
| Prepaid expenses and other current assets | 540,499 | 703,194 |
| Total assets | $7,978,634 | $6,944,488 |
| Liabilities and Stockholders’ Equity: | ||
| Liabilities: | ||
| Accounts payable | $866,028 | $496,702 |
| Accrued and other current liabilities | 757,588 | 425,932 |
| Total liabilities | 1,623,616 | 922,634 |
| Commitments and Contingencies (see Note 7) | ||
| Stockholders’ Equity: | ||
| Common Stock, par value $0.0001, 250,000,000 shares authorized as of December 31, 2023, and 2022; 3,930,840 and 770,115 shares issued and outstanding as of December 31, 2023, and 2022, respectively. | 393 | 77 |
| Additional paid-in capital | 59,742,503 | 51,614,965 |
| Accumulated deficit | (53,387,878) | (45,593,188) |
| Total stockholders’ equity | 6,355,018 | 6,021,854 |
| Total liabilities and stockholders’ equity | $7,978,634 | $6,944,488 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.